Con: does shockwave therapy have a place in the treatment of Peyronie’s disease?
Opinion

Con: does shockwave therapy have a place in the treatment of Peyronie’s disease?

Abdullah Alkhayal, Serge Carrier

Department of Urology, Royal Victoria hospital, McGil University, Montreal, Québec, Canada

Correspondence to: Dr. Serge Carrier. Royal Victoria hospital/ McGill University, 1001 Blvd Decarie, Room D05.5726, Montreal, Quebec, H4A 3J1, Canada. Email: serge.carrier@mcgill.ca.

Submitted Feb 18, 2016. Accepted for publication Mar 02, 2016.

doi: 10.21037/tau.2016.03.20


Introduction

Extracorporeal Shockwave Therapy (ESWT) has been used to treat various urological conditions such as nephrolithiasis and erectile dysfunction. The use of ESWT for Peyronie’s disease (PD) has been a subject of debate since Bellorofobate et al. published the first report on the use of ESWT on a PD patient in 1989 (1). The mechanism of action of ESWT in PD patients is still unknown mainly due to the lack of an animal model truly resembling PD. Multiple theories had been hypothesized with regards to its mechanism of action. Levine hypothesized that EWST causes destruction and lysis of the plaque by inducing an inflammatory response that attracts macrophages to the plaque site, leading to changes in vascularity and plaque resorption (2). In addition, direct trauma caused by ESWT may produce scar formation on the contralateral side of the penile shaft and, thus, correct the curvature. The other possible theory is that ESWT causes degradation of the plaque leading to an increase of the surface area in contact with the drugs introduced either locally or systemically (3). None of these theories have, however, yet to be scientifically proven.

Many papers have been published, but very few are well structured. Hauck et al. (4) published a meta-analysis of 17 studies that evaluated the effects of ESWT on PD patients. They concluded that the effect of ESWT on PD patients is still questionable and must be evaluated in a randomized manner. Their initial results revealed a possible positive effect on penile pain and sexual function. Since then, four randomized clinical trials (RCTs) have been published. In this paper, we evaluate these RCTs and assess the effects of ESWT on PD patients from different aspects, namely pain, curvature, erectile function, and plaque size. We also analyze the best studies and offer our opinions and recommendations.


Literature review

Palmieri et al. (5) reported the first placebo-controlled RCT to evaluate the effect of ESWT on PD patients. The study included 100 patients with less than a 12-month history of PD; patients were divided into two groups of 50. The intervention group received 2,000 shockwaves, under the Storz Duolith ESWT system, for four weekly treatment sessions. The goal of the study was to evaluate the therapeutic advantage in treatment-naïve patients. The primary end points were not stated in the manuscript, and there were no sample size power calculations. Patients were followed for 12 and 24 weeks post-treatment. The results showed significant statistical improvement in pain, quality of life (QoL), and IIEF-5 score between the two groups and from baseline to 12 and 24 weeks. In terms of pain, there was an improvement by five points in the ESWT group compared with the control group. Further, 83% of patients reported pain improvement in the ESWT group compared with 43% in the placebo arm. IIEF-5 also improved by five points in the ESWT group compared with stability in the control arm over the follow-up period. Penile curvature did not differ significantly between the two groups, but the placebo arm showed some worsening of penile curvature from baseline, while the ESWT group showed a stable curve. These authors concluded that ESWT led to pain resolution and improved QoL and erectile function over the study period.

However, Palmieri et al. (5) recognized some study limitations, including the restricted inclusion criteria, which did not represent real day-to-day life. The QoL questionnaire was not validated, and the cause of erectile dysfunction was not characterized. This paper has been criticized for its short follow-up and subjective outcomes. Further, the authors used the visual analogue scale (VAS) to assess the improvement in pain; however, it is not clear if it was used during the primary assessment where the pain caused by the injection itself would contribute to the VAS results. Alternatively, it may have been completed afterward, potentially leading to recall bias. Further, the VAS was not validated for situational pain.

Chitale et al. (6) published the second RCT, in which they compared ESWT to a sham treatment. The end point was to assess the change in penile curvature and IIEF-5 improvement. This study aimed to have 50 patients in each arm, but the authors were able to recruit only 36. Sixteen patients received ESWT, and 20 patients were in the control arm. The intervention group received six weekly sessions of 3,000 shocks per session. Half of the patients had been having their symptoms for more than 12 months with the mean symptom duration being 24 months. In this trial, only 14 patients had a painful erection despite a long-standing stable deformity, which makes it difficult to draw conclusions about pain management from this study. There was no significant positive influence of ESWT on any of the outcomes. However, although not statistically significant, the patients in the ESWT group had more of a deterioration of dorsal curvature and further penile shortening compared with the control arm. The other variables were the IIEF-5 score, VAS score, and global assessment questionnaire. The study has been criticized for its small sample size and short follow-up.

Palmieri and colleagues (7) reported another RCT that compares the use of ESWT alone to the use of ESWT and 5 mg tadalafil daily. They included 100 patients and followed up for four weeks. The main outcomes were the IIEF-5 score, pain improvement using the VAS score, penile curvature, and QoL. The results showed no statistically significant improvement in penile curvature or plaque size between the two groups or from baseline. However, pain improved by four to five points on the VAS in both groups. The IIEF-5 score was better in the tadalafil + ESWT group compared with the ESWT alone group, which confirms the minimal role of ESWT in improving erectile function and the added benefit of the phosphodiesterase-5 inhibitor (PD5I). QoL was better in the tadalafil + ESWT group compared with the ESWT alone group, which could be a result of improving erection and sexual life. This was a well-designed study. However, adding two other comparison arms to the study would have provided it with further validity. A third group could receive a sham treatment and a fourth group could receive only tadalafil. The only conclusion that can be drawn from this study is that PD5I is beneficial for patients with PD.

Hatzichristodoulou and colleagues (8) reported the fourth RCT, which involved patients with PD randomized to ESWT or placebo groups by using the Piezoson 100 lithotripter. They used 2,000 shockwaves per session for six weekly sessions. The primary end point was a decrease in pain between baseline and follow-up. The secondary outcomes were changes in penile curvature, plaque size, and sexual function. Pain was assessed with the VAS, while sexual function was assessed by a self-completed, non-validated questionnaire; 51 patients in each group were included. The results supported Palmieri’s findings. Altogether, 85% of the patients in the ESWT group compared with 48% in the placebo group had pain improvement, with a significant difference between the two groups. However, the study was powered as 100% of the patients had pain, whereas only 45 of the included patients actually experienced pain. There was a worsening of penile curvature in 40% of the patients in the ESWT group in contrast to only 24% in the placebo group. However, that result was not statistically significant. Plaque size decreased in 39% of the patients in the ESWT group compared with 18% in the control arm. However, 10% of the patients in the ESWT group had a plaque size increase. A large percentage of patients had minor side effects, mainly local petechial bleeding in 80% of the patients in the ESWT group. In summary, although this study showed an improvement in pain and a higher percentage of pain resolution in the treatment group, it also affected and worsened penile curvature and plaque size. This may complicate future intervention, if needed, as well as QoL, which was not assessed in this paper.

Table 1 summarizes the main findings and weaknesses of randomized controlled trials evaluating the role of ESWT for the management of PD.

Table 1
Table 1 Summary of randomized controlled trials evaluating the effect of ESWT for the management of Peyronie’s disease
Full table

Discussion

While ESWT is a novel method of treating PD, its mode of action and efficacy remain questionable. Four RCTs have evaluated this subject, and the results are inconsistent and confusing owing to their different shockwave generators and protocols as well as inclusion and exclusion criteria.

Penile pain is a common symptom of PD. It presents in 30% to 40% of patients in the early stage of the disease (9). The RCTs evaluating the effect of ESWT on PD patients suggested some added benefit of ESWT in pain resolution and improvement in 3 out of 4 trials. These trials were hindered by the small sample size, short follow-up duration, and some statistical flows. The natural history of pain associated with PD has been reported in the literature to have a spontaneous resolution with no interventions in the majority of patients (up to 80%) (10). In the ESWT literature, several studies have reported a positive effect of ESWT on penile pain, as evaluated by using the VAS (5-8). In these studies, when the ESWT group was compared with the control group, the improvement in pain ranged from four to five points in the VAS for the ESWT group compared with one to three points for the control group. Hence, the use of the VAS to assess pain is the main criticism of these studies, as pain is mostly situational and associated with an erection. To our knowledge, the VAS has never been used to assess situational pain that occurs, mainly, with an erection. Another point is that it is not clear if the VAS was used at the time of an artificial erection during the Doppler study or during a normal visit. Both situations are subject to bias as, in the first situation, the high VAS score may have been secondary to the pain caused by the injection, while in the second situation, recall bias may have played a role.

Two out of four trials showed an increase in penile curvature in the ESWT group in up to 40% of patients (6,8). By recommending ESWT for PD patients, we are exposing them to the harmful effects of the treatment. Hatzichristodoulou et al. (8) suggested that the use of ESWT should be reserved only for refectory cases after a trial of anti-inflammatory medications and analgesics or if pain persists despite the stability of the disease. The effect of ESWT on penile curvature is worrisome and it should be disclosed to patients if ESWT is offered.

Erectile functions were assessed by IIEF-5 (5-7) and a self-completed questionnaire (8). The two trials by Palmieri et al. showed significant improvement in the IIEF-5 score. The added benefit of tadalafil is clear in the study by Palmieri et al. (7). It is difficult to interpret these results unless we have a third group who received tadalafil only. We think if a third group received only tadalafil, we may see a similar improvement in the IIEF-5 score. The long-term effect of ESWT on erectile function is still questionable and it is unclear whether this benefit is durable after the 24-week study period. The study by Chitale et al. (6) showed no significant improvement in the IIEF-5 questionnaire. In addition, Hatzichristodoulou et al. (8) did not show any significant improvement in sexual activity.

One theory of the effect of ESWT on PD patients is the direct breakage of the plaque by shockwaves. However, none of the randomized trials (5-8) showed a significant improvement in plaque size compared with the control arm. Moreover, there was some worsening in plaque size in the ESWT group (8), which is concerning and may complicate further management.

Most papers reported the rate of acute side effects, including petechial hemorrhage, penile hematoma, increasing penile pain, and urethral bleeding. None reported rates of late side effects and long-term results. We still question how anyone would recommend a treatment modality without knowing what will happen after the study period.

Another point that must be mentioned here is the cost-effectiveness of the treatment imposed on patients and the healthcare system. This stems from the off-work days taken to be present for four to six treatment sessions and the cost of each session. This issue should be carefully assessed before recommending a questionable treatment modality for any patient outside a study protocol.

Finally, the American Urology Association recently published the first guidelines on the management of PD (11). It based its recommendation on the best available literature analyzed earlier. It recommended against the use of ESWT to treat penile curvature or plaques. Further, it added that clinicians may offer ESWT to improve penile pain, stating that “it is the opinion of the Panel that the overall utility of ESWT in the management of PD is low.” Hence, the decision to offer ESWT for pain management is left for the treating urologist without strong recommendation.


Conclusions

Based on the available evidence and after more than a decade of ESWT application on PD patients, we find the data to be insufficiently convincing to recommend the use of ESWT in patients with PD for any reason. A multicenter, randomized, double-blind, controlled clinical trial with a large sample size and long-term follow-up duration is therefore needed.


Acknowledgements

None.


Footnote

Conflicts of Interest: Dr. S Carrier provided a presentation and participated on the Eli Lilly advisory board; A Alkhayal has no conflicts of interest to declare.


References

  1. Bellorofonte C, Ruoppolo M, Tura M, et al. Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital Urol Nefrol Androl 1989;61:417-22. [PubMed]
  2. Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003;15 Suppl 5:S113-20. [Crossref] [PubMed]
  3. Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets 2012;11:48-57. [Crossref] [PubMed]
  4. Hauck EW, Mueller UO, Bschleipfer T, et al. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol 2004;171:740-5. [Crossref] [PubMed]
  5. Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-9. [Crossref] [PubMed]
  6. Chitale S, Morsey M, Swift L, et al. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU Int 2010;106:1352-6. [Crossref] [PubMed]
  7. Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35:190-5. [Crossref] [PubMed]
  8. Hatzichristodoulou G, Meisner C, Gschwend JE, et al. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013;10:2815-21. [Crossref] [PubMed]
  9. Bekos A, Arvaniti M, Hatzimouratidis K, et al. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol 2008;53:644-50. [Crossref] [PubMed]
  10. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;175:2115-8; discussion 2118. [Crossref] [PubMed]
  11. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's disease: AUA guideline. J Urol 2015;194:745-53. [Crossref] [PubMed]
Cite this article as: Alkhayal A, Carrier S. Con: does shockwave therapy have a place in the treatment of Peyronie’s disease? Transl Androl Urol 2016;5(3):371-374. doi: 10.21037/tau.2016.03.20